60 related articles for article (PubMed ID: 34649645)
1. Effectiveness and safety of mogamulizumab for the treatment of Sézary syndrome in very elderly patients: A real-world, multicentre, retrospective study conducted in France.
Ribereau-Gayon E; Beylot-Barry M; De Masson A; Ram-Wolff C; Bagot M; Pham-Ledard A; Grange F
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38804019
[No Abstract] [Full Text] [Related]
2. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.
Kim YH; Khodadoust M; de Masson A; Moins-Teisserenc H; Ito T; Dwyer K; Herr F; Bagot M
Eur J Cancer; 2021 Oct; 156 Suppl 1():S48-S49. PubMed ID: 34649658
[No Abstract] [Full Text] [Related]
4. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Antibodies in Cancer Treatment in the UK.
Eltarhoni K; Kamel F; Ihebunezie K; Nisar P; Soloviev M
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498915
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience.
Polgárová K; Polívka J; Kodet O; Klener P; Trněný M
Front Oncol; 2022; 12():884091. PubMed ID: 35747818
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of prognosis-associated DNA repair gene signatures in colorectal cancer.
Song D; Zhang D; Chen S; Wu J; Hao Q; Zhao L; Ren H; Du N
Sci Rep; 2022 Apr; 12(1):6946. PubMed ID: 35484177
[TBL] [Abstract][Full Text] [Related]
8. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
9. Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.
Remák E; Hawkins N; Jones T; Otley M; Twigger R; Prince M
Eur J Cancer; 2021 Oct; 156 Suppl 1():S18. PubMed ID: 34649645
[No Abstract] [Full Text] [Related]
10. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
[No Abstract] [Full Text] [Related]
11. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
12. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
14. Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz S; Zinzani PL; Bagot M; Kim YH; Moskowitz AJ; Porcu P; Dwyer K; Sun W; Herr FM; Scarisbrick J
Leuk Lymphoma; 2021 Dec; 62(13):3109-3118. PubMed ID: 34304674
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
